On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.

Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.

From January 13-16 2020, Novartis attended the J.P Morgan Healthcare Conference in San Francisco.

The World Health Organization (WHO) passed a resolution on psoriasis that creates an urgent call to action for the international community.

Novartis is partnering with the International Committee of the Red Cross (ICRC) to improve care and treatment for Syrian refugees in Lebanon suffering from chronic diseases.

Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.

Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.